Keryx Pharmaceuticals Inc.'s largest Medicare Part D plan sponsor in the United States has added the company’s Auryxia drug to its Medicare Part D plan formularies.
Auryxia is approved in the U.S. for controlling serum phosphorous levels in patients suffering from chronic kidney disease (CKD) on dialysis. Keryx noted in a press release that roughly 450,000 people in the U.S. who have End Stage Renal Disease require dialysis treatment; many of these people now have increased unrestricted access with the Part D plan addition.
“We are pleased that another large insurance provider has recognized the value that Auryxia can bring to patients,” Greg Madison, president and CEO of Keryx Biopharmaceuticals, said in a statement. “The addition to these formularies, which covers both the remainder of 2017 and the full year 2018, will support continuing growth of Auryxia in dialysis as well as ensuring that we can provide broad access to Auryxia for people with iron deficiency anemia (IDA) and non-dialysis dependent (NDD) CKD, pending approval of this indication later this year.”